Table 1 Characteristics of studies included in Meta-analysis
Study | Country | Surgical setting | Age (yr) | ASA | Administration method | Group (n, patients) | Outcomes |
|---|---|---|---|---|---|---|---|
Younghoon Jeon 2010 | Korea | Elective surgery | 45.4 ± 11.1 45.9 ± 14.2 50.1 ± 10.6 | I-II | IVVO | N S (n = 39) lidocaine 40 mg (n = 39) paracetamol 50 mg (n = 40) | A/B/C/D |
Yonghong Zhang 2012 | China | Elective surgery | 45.18 ± 12.44 41.28 ± 14.12 45.24 ± 14.36 43.54 ± 15.01 | I-II | IVVO | N S (n = 40) lidocaine 40 mg(n = 40) parecoxib 20 mg(n = 40) parecoxib 40 mg(n = 40) | A/B/C/D |
Younghoon Jeon 2013 | Korea | Elective surgery | 46.8 ± 11.5 48.5 ± 13.1 46.2 ± 16.3 | I-II | IVVO | placebo(n = 35) lidocaine 20 mg(n = 35) ketorolac 10 mg(n = 35) | A/B/C/D |
Gülnaz Ateş 2014 | Turkey | Elective surgery | 36.45 ± 12.94 35.58 ± 11.9 39.27 ± 11.81 | I-II | IVVO | N S (n = 60) lidocaine 40 mg(n = 60) paracetamol 50 mg(n = 60) | A/B/C/D |
Sennur Uzun 2014 | Turkey | 3 kinds of elective surgeries | 41.8 ± 13.9 42.7 ± 11.9 41.7 ± 13.3 | I-II | IVVO | N S(n = 50) lidocaine 40 mg(n = 50) aracetamol 50 mg(n = 50) | A/B/C/D |
Cheng Yuan 2014 | China | Elective surgery | 45.8 ± 10.3 46.9 ± 9.6 44.3 ± 9.8 43.7 ± 10.6 | I-II | IV IVVO IV IVVO | N S (n = 20) N S (n = 20) flurbiprofen 50 mg(n = 20) flurbiprofen 50 mg(n = 20) | A/B/D |
Li Sha 2014 | China | Elective surgery | 46.7 ± 11.1 48.4 ± 13.2 46.2 ± 14.6 | I-II | IVVO | N S (n = 35) lidocaine 40 mg (n = 35) flurbiprofen 50 mg(n = 35) | A/B/C/D |
Ma Qingjie 2016 | China | Elective surgery | 39.2 ± 3.7 38.5 ± 4.1 40.3 ± 5.2 | I | IV | N S (n = 40) parecoxib20mg (n = 40) parecoxib40mg (n = 40) | A/B |
Yu Liang 2018 | China | Elective surgery | 40.7 ± 8.7 42.7 ± 7.7 43.7 ± 7.3 | I-II | IV | N S (n = 20) lornoxicam 4 mg(n = 20) lornoxicam 8 mg(n = 20) | A/B |